Effects of recombinant erythropoietin (r‐HuEPO) on plasma glucose concentration in endurance‐trained rats

Cayla, J; Lavoie, Claude; Gareau, R; Duvallet, Alain

doi:10.1046/j.1365-201x.1999.00565.x

Cited by 9 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three days of injections with high-dose rHuEpo did not induce changes in the AV difference for glucose in healthy humans (38). In contradiction to the results in the present acute study, animal studies with prolonged Epo treatment have shown a reduction in basal resting plasma glucose levels (6,9), improved glycemic control, and reduced body weight (24). However, in support of our data, Epo treatment in wild-type mice showed no changes in insulin sensitivity, although a glucose-lowering effect of the treatment was found (9).…”

Section: Discussioncontrasting

confidence: 99%

Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men

Christensen

Vendelbo

Krusenstjerna-Hafstrøm

et al. 2012

Journal of Applied Physiology

View full text Add to dashboard Cite

Treatment with recombinant human erythropoietin (rHuEpo) improves insulin sensitivity in patients with end-stage renal disease, and animal studies indicate that Epo increases fat oxidation. However, the metabolic effects of rHuEpo have never been experimentally studied in healthy humans. The aim was to investigate the effects of an acute rHuEpo bolus on substrate metabolism and insulin sensitivity in healthy young men. Ten healthy young men were studied in a single-blinded, randomized crossover design with a 2-wk washout period receiving 400 IU/kg rHuEpo or placebo. Substrate metabolism was evaluated by indirect calorimetry and tracer infusions, and insulin sensitivity by a hyperinsulinemic euglycemic clamp; and PCR and Western blotting measured protein expression and content, respectively. Resting energy expenditure (REE) increased significantly after rHuEpo [basal: 1,863.3 ± 67.2 (kcal/day) (placebo) vs. 2,041.6 ± 81.2 (rHuEpo), P < 0.001; clamp: 1,903.9 ± 68.3 (placebo) vs. 2,015.7 ± 114.4 (rHuEpo), P = 0.03], but the increase could not be explained by changes in mRNA levels of uncoupling protein 2 or 3. Fat oxidation in the basal state tended to be higher after rHuEpo but could not be explained by changes in mRNA levels of CPT1 and PPARα or AMPK and ACC protein phosphorylation. Insulin-stimulated glucose disposal, glucose metabolism, and whole body and forearm protein metabolism did not change significantly in response to rHuEpo. In conclusion, a single injection of rHuEpo acutely increases REE in healthy human subjects. This calorigenic effect is not accompanied by distinct alterations in the pattern of substrate metabolism or insulin sensitivity.

show abstract

Section: Discussioncontrasting

confidence: 99%

Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men

Christensen

Vendelbo

Krusenstjerna-Hafstrøm

et al. 2012

Journal of Applied Physiology

View full text Add to dashboard Cite

show abstract

“…Given that our glucose uptake studies showed Akt-dependent increases with EPO, together with earlier reports assuming that EPO treatment resulted in alterations in the striated muscle of endurance-trained rats [ 30 ] , we also examined whether EPO could promote the shift of GLUT4 to the cell membrane in 3T3-L1 adipocytes as well. We showed that intense GLUT4 translocation ( • ▶ Fig.…”

Section: Discussionmentioning

confidence: 96%

Effects of Erythropoietin on Glucose Metabolism

et al. 2012

View full text Add to dashboard Cite

We purposed to determine the impact of erythropoietin on altering glucose metabolism in the settings of in vitro and in vivo experiments. The acute effect of erythropoietin on lowering blood glucose levels was studied in animal experiments. In [³H]-deoxy-D-glucose isotope studies we measured glucose uptake with insulin and erythropoietin using 3T3-L1 cells cultured under normal or high glucose conditions. Altered activation of Akt and ERK pathways was evaluated in immunoblot analyses. Immunocytochemistry was conducted to determine the glucose transporter 4 translocation to the plasma membrane. Addition of erythropoietin significantly lowered blood glucose levels in vivo in rats. The glucose uptake was markedly increased by erythropoietin treatment (at concentrations 0.15, 0.3, and 0.625 ng/ml) in adipocytes grown in high glucose medium (p<0.05), but it remained unaltered in cells under normal glucose conditions. Significant increase of phosphorylation of ERK and Akt was detected due to erythropoietin (p<0.05). Co-administration of erythropoietin and insulin resulted in higher phosphorylation of Akt and [³H]-deoxy-D-glucose uptake in adipocytes than insulin treatment alone. We found that erythropoietin induced the trafficking of glucose transporter 4 to the plasma membrane. Our data showed that erythropoietin significantly decreased blood glucose levels both in vivo and in vitro, in part, by increasing glucose uptake via the activation of Akt pathway. Preliminary data revealed that adipocytes most likely exhibit a specific receptor for erythropoietin.

show abstract

“…Others factors could have also contributed to the decrease of lactatemia. Several studies have suggested that rHuEPO may modify substrate oxidation and lactate metabolism at rest and during exercise (6,23,26,28). Lavoie et al (23) reported changes in substrate oxidation during exercise and a lower muscle lactate concentration at the end of exercise in animal models after repeated injections of rHuEPO compared with placebo-treated rats.…”

Section: Discussionmentioning

confidence: 99%

Injections of recombinant human erythropoietin increases lactate influx into erythrocytes

Connes¹,

Caillaud²,

Mercier³

et al. 2004

Journal of Applied Physiology

View full text Add to dashboard Cite

Previous studies showed that erythropoietin not only increases erythrocyte production but is also essential in both the synthesis and the good functioning of several erythrocyte membrane proteins, including band 3. It is still unknown whether anion and/or H(+) fluxes are modified by erythropoietin. This study aimed to evaluate the effect of recombinant human erythropoietin (rHuEPO) injections on lactate transport into erythrocytes via band 3 and H(+)-monocarboxylate transporter MCT-1, two proteins involved in lactate exchange. Nine athletes received subcutaneous rHuEPO (50 U/kg body mass 3 times a week for 4 wk), and seven athletes received a saline solution (placebo group). All subjects were also supplemented with oral iron and vitamins B(9) and B(12). Lactate transport into erythrocytes was studied before and after the rHuEPO treatment at different lactate concentrations (1.6, 8.1, 41, and 81.1 mM). After treatment, MCT-1 lactate uptake was increased at 1.6, 41 (P < 0.01), and 81.1 mM lactate concentration (P < 0.001) although lactate uptake via band 3 and nonionic diffusion were unchanged. MCT-1 maximal velocity increased in the rHuEPO group (P < 0.05), reaching higher values than in the placebo group (P < 0.05) after treatment. Our results show that rHuEPO injections increased MCT-1 lactate influx at low and high lactate concentrations. The increase in MCT-1 maximal velocity suggests that rHuEPO may stimulate MCT-1 synthesis during erythrocyte formation in bone marrow.

show abstract

Effects of recombinant erythropoietin (r‐HuEPO) on plasma glucose concentration in endurance‐trained rats

Cited by 9 publications

References 6 publications

Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men

Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men

Effects of Erythropoietin on Glucose Metabolism

Injections of recombinant human erythropoietin increases lactate influx into erythrocytes

Contact Info

Product

Resources

About